Disparities in the Use of Radiation Therapy for Postlumpectomy Breast Cancer by Rothley, Deborah
Walden University 
ScholarWorks 
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral Studies Collection 
2021 




Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations 
 Part of the Oncology Commons, and the Public Health Education and Promotion Commons 
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies 
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an 























has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Nancy Rea, Committee Chairperson, Public Health Faculty 
Dr. Mary Lou Gutierrez, Committee Member, Public Health Faculty 






Chief Academic Officer and Provost 
















MSPH, University of South Carolina, 1990 
BS, University of South Carolina, 1985 
 
 
Doctoral Study Submitted in Partial Fulfillment 
Of the Requirements for the Degree of 








Early-stage breast cancer can be highly curable when properly treated using national 
standards of care. However, disparities in treatment, including radiation therapy after 
lumpectomy, may result in disproportional mortality rates in African American women. 
The purpose of this study was to add to the body of research to help determine the 
reasons for an underutilization of radiation therapy among African American women and 
whether the disparity has continued by analyzing recent patient data. Anderson’s 
behavioral model was used to frame the study and help determine the associations 
between the predisposing and enabling independent variables of race, age, health 
insurance status, and residential urbanicity and the dependent variable of radiation 
therapy use. This retrospective quantitative study used data from the National Cancer 
Institute Surveillance, Epidemiology, and End Results Program of women in Georgia 
diagnosed with early-stage breast cancer between 2012–2016. Logistic regression 
analysis of case files indicated that there were no statistically significant racial 
association, (p = .517), after controlling for age, in receiving radiation therapy after 
lumpectomy in Georgia.  Furthermore, logistic regression analysis indicated that 
residential urbanicity and health insurance status did not significantly predict radiation 
therapy usage among women with early-stage breast cancer after controlling for race and 
age. The findings were not significant and did not show an increase in use of critical 
radiation treatment by African Americans. These results justify an expansion of 
interventions by cancer facilities to increase breast cancer treatment with radiation 
therapy. Appropriate treatment may improve survival rates of African Americans and 
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Section 1: Foundation of the Study and Literature Review 
In the United States, the most common cancer among women is breast cancer, 
with 1 in 8 women developing the disease (Siegel et al., 2018). While the death rate from 
female breast cancer has dropped significantly over the past few decades, in 2018 it was 
still the second leading cause of cancer death among women (Siegel et al., 2018). With 
more than 40,000 women dying across the country in 2018, efforts to improve the 
prevention, early detection, and treatment of breast cancer remain paramount in the 
medical community. While great advances have been made in these regards, survival has 
not been affected equally in all segments of the U.S. population (Sighoko et al., 2018). 
Health disparities exist in populations defined by geographic location and race, with 
complex and ambiguous causes.  
Survivability of breast cancer, and especially early-stage breast cancer, depends 
on proper treatment. As part of the National Cancer Institute (NCI), the National 
Comprehensive Cancer Network’s (NCCN) guideline for the treatment of most early-
stage breast cancer recommends breast-conserving surgery with radiation therapy to 
follow for definitive local therapy (NCCN, 2019b). However, even though radiation 
therapy after breast- conserving surgery is considered the standard of care in the United 
States, many women do not receive this important treatment. In this study, I examined the 
associations between African American and White women’s receipt of radiation therapy 
for treatment of early-stage breast cancer in Georgia. I also analyzed the patients’ health 
insurance status and the accessibility of treatment facilities to determine if they predicted 
the patients’ use of radiation therapy.  
2 
 
In this first section of the study, I provide the problem statement, the study’s 
purpose, and the research questions and hypotheses. The theoretical foundation for the 
study and the nature of the study with the key variables are described next. My 
exhaustive search of the literature revealed many articles related to the study topic, and I 
highlight the ones most relevant to the research questions. Definitions of terms used in 
the study are listed with citations for support. My assumptions, scope, and delimitations 
to be used for conducting this study are described next. Finally, I conclude by identifying 
the significance of the study and summarizing the section.  
Problem Statement 
Elimination of the cancer burden caused by disparities is the goal of many health 
care organizations with the belief that survival rates can be improved by the identification 
of the root causes of disparities (NCI, n.d.b). The disparity in breast cancer mortality 
between African American and White women is the largest disparity among racial groups 
and has widened over the past 30 years (McCarthy et al., 2015). In addition to racial 
differences in cancer mortality, cancer patients in rural areas of the United States die of 
their disease at a higher rate than those who live in cities (McLafferty et al., 2011).  
A factor on which survival outcome depends in all patients is that of their medical 
treatment, which includes surgery and radiation therapy when the NCCN guidelines are 
followed. There is a gap in the literature due to a lack of current studies using recent data 
to examine whether the trend of underutilization of radiation therapy following surgery 
has continued in African American women and those residing in rural areas. In this study, 
I addressed this gap by examining the most recent Surveillance, Epidemiology, and End 
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Results (SEER) data to determine the rates of proper receipt of radiation therapy in 
African Americans and rural populations in Georgia. The SEER (n.d.b) database contains 
cancer registry data from 18 geographic regions in the United States, including both the 
metropolitan Atlanta area and rural Georgia. To continue to provide interventions aimed 
at improving breast cancer care for vulnerable patients, research should remain current 
and at the forefront of public health investigation. 
Purpose of the Study 
The underutilization of radiation therapy after breast-conserving surgery signifies 
a severe health care concern for many women, and discovery of the reasons for this 
disparity is needed to improve breast cancer survival. Radiation therapy after breast-
conserving surgery is the standard of care in the United States for women with early-
stage breast cancer and reduces the risk of recurrence by two thirds (Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) et al., 2011; Fisher et al., 2002). The goal of 
this quantitative study was to answer several research questions to better understand some 
of the specific reasons for the underutilization of radiation therapy. The independent 
variables were race, health insurance status, and county of residence, while the dependent 
variable was radiation therapy use. My objective was to analyze the association between 
race, health insurance status, and residential urbanicity with the use of postlumpectomy 
radiation therapy. Because African American women experience the highest breast 
cancer mortality rate and White women have the lowest mortality rate due to breast 
cancer, only these races were examined (see Sighoko et al., 2018). Another reason for 
only including these two races was that the population of Georgia is comprised of about 
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60% Whites, 32% African Americans, and only 8% all other races (U.S. Census Bureau, 
n.d.). 
The disparities in breast cancer treatment and mortality are well documented in 
the literature. Breast cancer treatment guidelines have been developed to provide the best 
outcomes possible, but the disparities in guideline concordance impact mortality rates of 
vulnerable patients (Fang et al., 2018). The findings of this study extend the knowledge 
gained from previous research. As cancer treatment becomes more complex and more 
costly, the potential for disparities may only increase. It is important to continue to 
analyze the available data to determine whether efforts to improve access and quality of 
care have resulted in the receipt of adjuvant radiation therapy by greater numbers of 
underserved women and whether breast cancer mortality disparities are being reduced.  
Research Questions and Hypotheses 
RQ1: Is there an association between patient race (i.e., African American versus 
White) in the use of radiation therapy for treatment of early-stage breast cancer 
after controlling for age at diagnosis among women in Georgia? 
H01: There is no significant association between race in the use of 
radiation therapy for treatment of early-stage breast cancer after 
controlling for age at diagnosis among women in Georgia. 
Ha1: There is a significant association between race in the use of radiation 
therapy for treatment of early-stage breast cancer after controlling for age 
at diagnosis among women in Georgia. 
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RQ2: Does patients’ residence (i.e., rural versus urban) and health insurance 
status predict the use of radiation therapy for treatment of early-stage breast 
cancer after controlling for race (i.e., African American versus White) and age 
among women in Georgia? 
H01: Patients’ residence and health insurance status do not predict the use 
of radiation therapy for treatment of early-stage breast cancer after 
controlling for race (i.e., African American versus White) and age among 
women in Georgia. 
Ha1: Patients’ residence and health insurance status do significantly 
predict the use of radiation therapy for treatment of early-stage breast 
cancer after controlling for race (i.e., African American versus White) and 
age among women in Georgia. 
Theoretical Foundation for the Study 
 The theoretical framework for this study was Andersen’s behavioral model 
(ABM). This conceptual model is the most widely used for explaining variation in the use 
of health service (Fan et al., 2011). ABM was initially developed in 1960 and indicates 
that an individual’s use of health care services is dependent on their predisposing factors, 
enabling factors, and need for care (Andersen, 1995). Predisposing factors to use health 
services consist of demographics, social structure, and health beliefs. Enabling resources 
include those obtained from personal, family, and community. The need factors comprise 
self-perceived reasons why an individual would or would not use health services. These 
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need factors include behavioral characteristics that cannot be measured in the SEER 
database and are beyond the scope of this study. 
Predisposing demographic determinants include age, sex, and race and are 
variables with low degrees of mutability because they cannot be changed to alter health 
care utilization (Andersen, 1995). Therefore, the predisposing factors are generally used 
as independent variables in social studies. The enabling factors are income, insurance 
status, and health care facility access. These determinants are most changeable and 
contribute highly to the use of health services according to ABM.  
After multiple revisions of the model, Andersen changed the ABM to go beyond 
health care utilization and to use health outcome as the endpoint (Andersen et al., 2014; 
Babitsch et al., 2012). Figure 1 is a diagram of the application of ABM to this study and 
the bold case variables are those that are included. The desired outcome was local 













































In this quantitative study, I examined identifiable factors obtained from cancer 
registry databases, such as race, county of residence (i.e., accessibility), and health 
insurance status, to determine their association with the use of radiation therapy for the 
treatment of early-stage breast cancer.  
Nature of the Study 
 I used a retrospective, cross-sectional study design to determine the rates of 
receipt of radiation therapy for early-stage breast cancer in Georgia. Determination of 
cause and effect or reasons for the answers were possible in this quantitative study. A 
secondary database was used to determine whether the reported nationwide 
underutilization of radiation therapy by African American women and those living in 
rural areas are consistent in the state of Georgia. Furthermore, a correlational analysis 
showed which variables were associated with the omission of radiotherapy. The 
independent variables were race, health insurance status, and county of residence, while 
the dependent variable was radiation therapy use. The SEER database of the NCI was 
best suited for this study because it provided cancer statistics of the U.S. population, with 
specific registries from Atlanta, Greater Georgia, and Rural Georgia. The most current 
available version of the database included data from years up to 2016.  
Literature Search Strategy 
 The literature search strategy I employed involved extracting keywords from the 
research questions to aid in my search. The Thoreau multidatabase search in the Walden 
University Library website was primarily used. Other specific journal searches for 
articles published in the past 5 years were conducted in the Journal of the National 
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Cancer Institute, Cancer Epidemiology, Cancer from The American Cancer Society, The 
New England Journal of Medicine, Lancet Oncology, International Journal of Radiation 
Oncology, Biology and Physics, American Journal of Public Health, and American 
Journal of Clinical Oncology. Keywords and phrases included breast cancer disparities, 
cancer treatment disparities, racial inequalities in breast cancer, rural and urban 
residence disparities in breast cancer, radiation therapy treatment disparities in breast 
cancer, and cancer disparities in Georgia. The searches uncovered a wealth of scholarly 
journal articles, from which I gathered information for this study. The primary articles 
used for this doctoral study are categorized in the following subsections. 
Literature Review Related to Key Concepts 
 In this study, I examined the dependent factors related to the fact that African 
American women have higher mortality rates due to breast cancer than White women. 
These mortality differences have widened between 1979 and 2010, and a more recent 
study from 2018 showed that African American women still experienced the highest 
mortality rate from breast cancer compared to other racial groups (McCarthy et al., 2015; 
Sighoko et al., 2018). From an exhaustive search of the literature, I determined that the 
disparity was relevant in both breast cancer treatment and mortality. A distinctive 
difference between races existed in radiation therapy treatment and elimination of this 
disparity may lead to improved survival rates. 
Breast Cancer Statistics 
 The American Cancer Society compiles lists of incidence rates of new cancer 
cases and deaths from cancer for each type of cancer; these lists and charts are 
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categorized by sex, race, state, stage, year, and others (Siegel et al., 2019). The American 
Cancer Society publishes a document annually that contains updated cancer statistics 
across the country, from which the breast cancer statistics for this study were obtained 
(see Siegel et al., 2019). 
 In addition, the official federal statistics on cancer are published by the Centers 
for Disease Control and Prevention (CDC, n.d.b) using the combined cancer registries of 
the SEER program from the NCI and the CDC’s own National Program of Cancer 
Registries. These statistics allow researchers, clinicians, regulators, policymakers from 
the public, and the U.S. government to monitor cancer populations, evaluate the success 
of programs to prevent and diagnose cancer, and identify needs for cancer prevention 
(CDC, n.d.a). 
 The SEER Cancer Statistics Review is published on the SEER website and 
includes statistics from 1975 through 2016 (Howlader et al., 2019). It was released in 
April of 2019 and contains the most recent cancer incidence, mortality, survival, 
prevalence, and lifetime risk statistics. The tables and figures are presented in a pdf 
format and custom reports are easily generated for public use. 
Breast Cancer Treatment 
 The foremost reference documents on the treatment of breast cancer are the 
NCCN Clinical Practice Guidelines in Oncology. These documents contain guidelines for 
the clinical decision-making process for clinicians that are formulated by affiliated 
medical institutions (NCCN, n.d.). The recommendations are evidence based and are 
grounded in clinical trials from around the United States. The NCCN Guidelines are the 
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recognized standard for clinical policy in cancer care and are frequently updated as 
information becomes available (NCCN, 2019a).  
 The NCCN Guidelines, Version 2.2019, Invasive Breast Cancer contains the 
recommendations for treatment of all four stages of invasive breast cancer. There exists a 
noninvasive type of breast cancer, ductal carcinoma in situ, which is referred to as Stage 
0 and was not included in this study. The focus of this doctoral study is early-stage breast 
cancer, which is defined as Stage I and/or II for the purpose of this study (see NCCN, 
2019b). Stage I is defined by the American Joint Committee on Cancer (AJCC) as breast 
tumors 2 cm or smaller in size and that has not spread to any lymph nodes (NCCN, 
2019b). Stage II include those tumors that are between 2 cm and 5 cm, or cancer that has 
spread to the axillary lymph nodes (NCCN, 2019b). Stage II is a slightly more advanced 
form of the disease because it is either large or has spread beyond the original location. 
 The NCCN Guidelines for Stage I and II breast cancer recommend lumpectomy 
with a surgical staging of axillary lymph nodes (Gradishar et al., 2019). In the case of 
both negative and positive axillary nodes, radiation therapy is indicated as the 
recommended treatment by the NCCN following surgery. Another option that has similar 
outcome potential is a mastectomy, with or without radiation therapy (Fisher et al., 2002; 
Gradishar et al., 2019). Mastectomy is an option for those women who are unable or 
refuse to have a lumpectomy; however, radiation therapy is not typically indicated after 
mastectomy as it is postlumpectomy, except when surgical margins and/or nodes are 
positive (NCCN, 2019b). 
12 
 
Disparities in Breast Cancer Survival 
 According to a recent SEER Cancer Statistics Review, African American women 
have a 36% higher mortality rate due to breast cancer compared with White women 
(Howlader et al., 2019). Although this percentage included all stages of the disease and 
all ages, it demonstrates the racial disparities in breast cancer survival. The SEER review 
also noted that African American women have higher breast cancer mortality rates 
compared with White women despite a lower overall disease incidence (McCarthy et al., 
2015). This statement reflects the SEER data from 1975–2016 for women with breast 
cancer. Specifically, the age-adjusted incidence rate for White women in the United 
States was 136.6 per 100,000 women per year compared with 124.0 for African 
American women (Howlader et al., 2019). However, the mortality rate for White women 
was 20.6 per 100,000 per year compared with 28.1 for African American women. 
 Other researchers have come to the same conclusions in other studies regarding 
the incidence and mortality rate differences between African American and White 
women. A large examination of 20,025 women presenting with Stage I, II, or III breast 
cancer between January 2000 and December 2007 resulted in the conclusion that African 
Americans are more likely to die from their breast cancer than other races regardless of 
their tumor subtype or stage (Warner et al., 2015). In this NCCN Breast Cancer 
Outcomes Database study, overall African Americans had a 21% higher risk of breast 
cancer-specific death than White Americans, Hispanic Americans, and Asian Americans 
(Warner et al., 2015).  
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Although progress has been made in the past few decades in reducing the racial 
disparity in mortality from many types of cancer and cardiovascular disease, the mortality 
rates remain higher for African American women (McCarthy et al., 2015). However, in 
contrast to other diseases, the disparity in breast mortality among young women seems to 
be widening (McCarthy et al., 2015). 
 Research into breast cancer incidence and mortality disparities was also published 
by the CDC in 2016. The authors examined data from 2000 to 2014 in the United States 
Cancer Statistics database and concluded that there was a trend in increasing African 
American breast cancer mortality in women older than 50 years (Richardson et al., 2016). 
In order to demonstrate regional differences in racial disparity in breast cancer, the SEER 
database was used to gather incidence and mortality data from 2010 to 2014 in a study of 
racial differences by state (DeSantis et al., 2017). The authors observed that the incidence 
rate was significantly higher for African Americans living in southern states, Indiana, 
Michigan, and the District of Columbia (DeSantis et al., 2017). Furthermore, the 
mortality rates during the study period were higher in the southern states, the District of 
Columbia, and a few Southwestern and Midwestern states. The mortality per 100,000 
women ranged from 20.1 to 34.4, with the state of Georgia’s mortality rate at 29.2 
(DeSantis et al., 2017). The African American: White mortality ratio for Georgia was 
1.45.  
 In a study of breast cancer mortality in the 50 largest U.S. cities, Hunt and 
Hurlbert (2016) found that in 24 of the cities studied, African American women died at a 
higher rate than White women. In the Avon Foundation-sponsored study, they compared 
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the mortality rate ratio of two 5-year periods, 2005–2009 and 2010–2014. They ranked 
the 50 cities in order of relative mortality rate between the two races and showed that 
Atlanta, GA had the highest difference. Atlanta’s rate ratio increased by 113% from the 
earlier period to the most recent time period, with the relative difference in mortality 
between African American and White women with breast cancer being more than 2:1 
during 2010–2014. These results prompted the authors to advise that city-level data are 
important for planning effective public health interventions to improve breast cancer 
health care, treatment, and outcomes (Hunt & Hurlbert, 2016). 
Disparities in Rural Breast Cancer Patients 
 In 2017, researchers at the CDC found that the death rate from 17 different 
cancers in rural counties in the United States was 14% higher than the rate in large 
metropolitan areas during the study period of 2009–2013 (Henley et al., 2017). For 
female breast cancer, the rural/urban difference was 18%; however, the statistics were not 
divided into cancer stage. The authors suggested that factors such as environmental 
exposures, behavior, race, and access to care were contributors to the disparity. 
 In 2016, Congress funded the Cancer Moonshot with $1.8B over a 7-year period 
(NCI, n.d.a). This initiative was established to hasten cancer research, make treatment 
more accessible to patients, and improve the prevention and detection of cancer at an 
earlier stage. The Cancer Moonshot initiative emphasized the importance of increasing 
research into disparities between rural and urban cancer patients (Unger et al., 2018). 
With the recognition of this disparity, researchers have sought to determine if cancer 
outcomes in rural areas were due to inadequate access to quality cancer care, disease 
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type, socioeconomic status (SES), health insurance coverage, social structure, treatment, 
or other factors. In an effort to narrow down the possible reasons, researchers at the Fred 
Hutchinson Cancer Research Center analyzed the survival outcomes for rural cancer 
patients participating in clinical trials (Unger et al., 2018). The authors found that among 
patients enrolled in 44 NCI-sponsored Southwest Oncology Group (SWOG) treatment 
trials, including a wide variety of cancer types and stages, there were no differences in 
survival outcomes by residency status. This important finding showed that within a 
clinical trial setting, under similar treatment conditions, rural and urban residing patients 
have similar outcomes. Therefore, the authors suggested that the survival differences for 
rural and urban residing cancer patients may be partially due to inadequate receipt of 
guideline-concordant cancer care instead of reasons such as cancer stage and SES (Unger 
et al., 2018). Their study included clinical trials for 17 various cancer types and for 
hormone receptor-positive and negative breast cancers, the cancer-specific survival rate 
was slightly worse for rural patients versus urban residing patients (Unger et al., 2018). 
Not all rural- and urban-residing patients have access to clinical trials conducted by large 
academic institutions; therefore, the reasons for disparities in treatment options for cancer 
patients warrant further investigation. 
Radiation Therapy Disparities 
 The literature contained several articles that contained evidence showing there 
was a racial disparity in those who receive radiation therapy for breast cancer; however, 
most were not published in the last 5 years. As early as 1985, researchers recognized that 
radiation therapy was underutilized following breast-conserving surgery (BCS) in women 
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with early-stage breast cancer (Lazovich et al., 1991). The authors of this study, however, 
did not comment on differences between races and the use of radiation therapy as 
adjuvant treatment. Mandelblatt et al. (2002) found that even though the breast cancer 
mortality rates had begun to decline, African American women actually experienced an 
increase in mortality rates. The authors concluded that when African American women 
received breast-conserving surgery, they would be less likely than White women to 
receive radiation therapy. This was the first large-scale, nationally represented sample of 
women that compared treatment received by African Americans and Whites. Since then, 
there have been several other national and regional studies that associated racial 
disparities in the use of radiation therapy treatment. 
There were striking racial disparities in the types of therapy deemed necessary for 
breast cancer. Bickell et al. (2007) studied medical records of 677 women with breast 
cancer in New York City during 1999–2000. Their results were similar to those of 
Mandelblatt et al. (2002) and showed that racial minority women had twice the risk of 
White women for not receiving necessary adjuvant treatment for early-stage breast 
cancer. These conclusions were further verified by Sail et al. (2012) who studied records 
of 54,682 women with early-stage breast cancer and found that the percentage of women 
who did not receive radiation therapy after breast-conserving surgery increased from 
1992 to 2002. They also determined that the disparities in receipt of radiation therapy 
between African American and White women increased during the time period. Another 
large-scale study by Smith et al. (2010) used the national Medicare database to identify 
34,080 older women treated with BCS for invasive breast cancer in 2003. Substantial 
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racial disparities were found in radiation therapy use across the United States with 74% 
of White women receiving radiation therapy and 65% of African Americans. 
Suboptimal use of radiation use can be detrimental to survival. Gold et al. (2008), 
identified factors associated with suboptimal use of radiation therapy and how it impacted 
the survival of women diagnosed with early-stage breast cancer. The authors used SEER 
data and found that delays in incomplete radiation treatment resulted in a reduction in 
disease-free survival. While they did not associate the differences between racial groups, 
the results were important for future studies.  
In 2012, Tuttle et al. published a large-scaled nationwide study to determine 
which early-stage breast cancer patients do not receive radiation therapy after breast-
conserving surgery in the United States. This study was based on breast cancer 
population-based data from the SEER database from 1992 through 2007. Of the 294,000 
patients with nonmetastatic breast cancer who underwent surgery, 21% did not receive 
radiation therapy (Tuttle et al., 2012). The omission of radiation therapy increased during 
those years significantly for African American women and those considered high risk. 
The authors noted that the reasons for the increased omission were unclear, but they 
speculated as to some possibilities such as transportation, communication between 
medical specialists, and the side effects of radiation treatment.  
In 2012, Markossian and Hines examined the disparities in late-stage breast 
cancer in Georgia. The authors used SEER data from 1992-2007 to compare treatment 
and outcome by age, race, and rural/urban residence (Markossian & Hines, 2012). The 
objective of the study was to calculate odds ratio (OR) for receipt of surgery and adjuvant 
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treatment, OR for late-stage diagnosis, OR for risk of death, OR for age, and OR for 
residence locale. The authors stated that Georgia contained a high variation in urban and 
rural residence, and SES. And as part of the southeast, it had a greater percentage of 
African American that other parts of the United States. The results of the study were that 
urban residents were more likely to receive BCS and radiation therapy. Rural patients 
were more likely to receive a mastectomy and were characterized as having the lowest 
SES. Rural residents had 41% decreased odds of receiving radiation regardless of stage or 
race. African American women had 7% decreased odds of receiving radiation regardless 
of stage or residence (Markossian & Hines, 2012). As for mortality, the study found that 
African American women had a 50% increased risk of death due to breast cancer than 
White women, but this statistic did not consider the stage. Also determined was that there 
was not a significant association in mortality between rural and urban residents 
(Markossian & Hines, 2012). The authors noted that further research was necessary to 
address the associations between outcomes and treatment for various stages of breast 
cancer. This gap in the recent literature was explored in my doctoral study. 
Other publications became available that verified the racial disparities in radiation 
therapy used for the treatment of advanced-stage breast cancer (Loveland-Jones et al., 
2016; Martinez, Tseng, et al., 2012). Additional studies analyzed racial disparities in 
breast cancer for specific locations in the United States (Dragun et al., 2011; Markossian 
et al., 2014; Ohri et al., 2016; Parise et al., 2012; Peipins et al., 2013; Schroen et al., 
2005; Voti et al., 2006; Yeboa et al., 2016).  
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The literature supported the rationale that increased distance to radiation treatment 
centers reduced the likelihood of receipt of proper adjuvant therapy (Baldwin et al., 2012; 
Lin et al., 2018; Peipins et al., 2013; Unger et al., 2018). For many breast cancer patients 
who resided in rural areas, travel of greater than 50 miles was required to reach centers 
which offered radiation therapy. There was even evidence that the problem of rural 
treatment access affected African Americans more so than White women and rural 
women were less likely to complete their radiation treatment course than urban residing 
women (Martinez, Shah, et al., 2012; Unger et al., 2018). In addition to travel distance, 
there were other reasons that contribute to the rural/urban residence disparity in the use of 
radiation therapy including SES, social support, comorbidities, health insurance status, 
education, and regional medical practice patterns (Baldwin et al., 2012). A study 
examined women with early-stage breast cancer living in Kentucky and found there were 
significant disparities in the use of radiation therapy with those living in rural areas using 
radiation therapy less often (McClelland et al., 2017). 
A current study in the Advances in Radiation Oncology journal made use of 
SEER data of 2006–2011 to determine the frequency of racial disparities in guideline-
concordant cancer care for select cancers. The authors only examined postmastectomy 
Stage III breast cancer and found that African American patients were less likely than 
White patients to receive guideline-concordant care, as defined by NCCN Guidelines 
(Fang et al., 2018). In this study for Stage III breast cancer, the use of radiation was 53% 
in African Americans and 61% in White patients. 
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There was one recent (2014–2019) publication found that examined the racial 
disparities in the receipt of radiation therapy for early-stage breast cancer (Yeboa et al., 
2016). The authors in this article used SEER data for 2004–2009 to determine that the 
racial disparities in postlumpectomy radiation therapy increased over the time period. 
Although the use of lumpectomy with radiation therapy decreased by 3.1% in White 
women, the decrease was more than double that in African American women (Yeboa et 
al., 2016). The authors noted that appropriate receipt of radiation therapy for breast 
cancer was an important public health issue because in women under the age of 70, it 
reduces local cancer recurrence by about two thirds. Of the 67,124 women studied, there 
was a decrease in the use of postlumpectomy radiation therapy over the study period, and 
the decreased use was more prevalent in African Americans (Yeboa et al., 2016). The 
study also considered some underlying causes of the disparities such as health insurance 
status, the quality of the treating physicians and hospitals, the travel distance to treating 
facilities, the density of radiation oncologists per area, and the patients’ own perceptions 
of the medical field (Yeboa et al., 2016). All of these were speculative and warrant 
further study. 
Definitions 
The following terms were used throughout this study: 
Adjuvant therapy: In cancer treatment, adjuvant therapy is the additional 
treatment given after the primary treatment to lower the risk of recurrence. In breast 
cancer care, surgery is usually the first treatment, and the adjuvant therapy may include 
chemotherapy radiation therapy, and hormonal therapy (NCCN, 2019b) 
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Breast-conserving surgery: An operation that removes the cancer tumor and other 
surrounding tissue but not the whole breast is breast conserving (NCCN, 2019b). It is also 
called lumpectomy or breast sparing surgery. 
Early-stage breast cancer: Breast cancer that has not spread outside of the breast 
or adjacent lymph nodes is referred to as early stage. For the purpose of this study, the 
early stages will include Stage I and Stage II breast cancers (NCCN, 2019b). 
The focus of this doctoral study was early-stage breast which was defined as 
Stage I and II for the purpose of this study (NCCN, 2019b). Stage I is defined by the 
AJCC as breast tumors 2 cm or smaller in size and that has not spread to any lymph 
nodes (NCCN, 2019b). Stage II is divided into two parts. Stage IIA is defined as breast 
tumors that are no larger than 2 cm and have spread to a few axillary lymph nodes, or 
breast tumors between 2 cm and 5 cm that have not spread to lymph nodes (NCCN, 
2019b). Stage IIB are breast tumors between 2 cm and 5 cm that have spread to a few 
local lymph nodes, or tumors that are larger than 5 cm that has not spread (NCCN, 
2019b). Stage IIIA is often considered an early-stage breast cancer because it consists of 
tumors greater than 5 cm that has spread to local lymph nodes. However, Stage IIIA was 
not included in this study due to the discrepancy in publications, between which stages 
constitute “early-stage.” 
 It must be noted that breast cancer staging of groups 0-IV is generally used by 
patients and nononcology practitioners. It is easy to comprehend and considered layman’s 
terminology in the United States. The AJCC required that registries and clinicians use the 
TNM (tumor, node, and metastasis) staging categories in the United States because tumor 
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grading and biomarker testing were routinely available (Giuliano et al., 2017). Starting 
with the November 2018 submission of registry data, SEER began accepting data based 
on TNM staging. Beginning with cases diagnosed in January 2019, all cancer registries in 
the United States changed collecting stage using the TNM classification (SEER, n.d.a). 
Therefore, when accessing the SEER database for this study, early-stage breast cancers 
were included T1-2, N0-1, M0 disease. This classification referred to tumors < 5 cm 
without extension to the chest wall, negative lymph nodes or positive axillary nodes, and 
no metastatic disease (Giuliano et al., 2017). 
Insurance: The SEER category of Insurance includes codes for uninsured, any 
Medicaid, insured, and insured/no specifics will be used for this study. 
Mortality rate: Mortality is used as a term used for the incidence of death in this 
study. It is defined as the number of deaths over a certain period of time or within a given 
group of people, and often described as an annual rate per 100,000 (Zeegers et al., 2016) 
NCI: The NCI is the U.S. government’s principal agency for cancer research and 
training and is part of the National Institutes of Health (NCI, 2018). 
NCCN:  The NCCN is an alliance of 28 leading cancer centers devoted to patient 
care, research, and education (NCCN, 2019a). NCCN publishes Clinical Practice 
Guidelines in Oncology are evidence-based documents that detail the sequential 
management and interventions that apply to all cancers in the United States. The NCCN 
Guidelines are continuously updated to reflect new clinical data as available and are 




National Institutes of Health: The National Institutes of Health is a U.S. federal 
agency that conducts research and supports the research of scientists in universities, 
hospitals, and research institutions. It is the largest biomedical research agency in the 
world (National Institutes of Health, 2019). 
 Race: The SEER category of race/ethnicity will be examined. Only the codes for 
White and African American are relevant to this study. 
Radiation oncologist: A radiation oncologist is a medical physician trained to 
treat cancer with ionizing radiation (American Cancer Society, n.d.). 
Radiation: The SEER category of Rx summary – radiation has codes for several 
types of radiation therapy. “External beam,” “radioactive implant,” “combination,” 
“radiation NOS,” and “other” codes were relevant to this study. However, the codes for 
“patient refused radiation therapy,” and “radiation recommended but unknown if 
administered” were indicated that radiation was not received. 
Radiation therapy: Radiation therapy or radiotherapy, is the use of high energy 
ionizing radiation to kill cancer cells and shrink tumors (NCCN, 2019b) 
Residence: The SEER category of state-county was analyzed for the location of 
residence. The Rural Georgia SEER Registry included 10 counties: Glascock Greene, 
Hancock, Jasper, Jefferson, Morgan, Putnam, Taliaferro, Warren, and Washington 
counties (Georgia Center for Cancer Statistics, 2010). The Atlanta SEER Registry was 
used to gather urban residing patient data and includes the counties of Clayton, Cobb, 
Dekalb, Fulton, and Gwinnett (Georgia Center for Cancer Statistics, 2010). 
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SEER: SEER is a U.S. federal program to collect cancer statistics and is supported 
by NCI. SEER gathers and publishes data from population-based cancer registries that 
comprise about 35% of the U.S. population (SEER, n.d.b). The program comprises a 
national database with information on patient demographics, tumor site and stage, 
treatment, and follow-up status. It also charts cancer incidence and survival and reports 
that information to other federal agencies such as the National Center for Health Statics 
(Duggan et al., 2016). 
Surgical oncologist: A surgical oncologist is a medical specialist who is trained to 
perform surgical biopsies and remove tumors in cancer patients. The surgical oncologist 
typically treats breast cancer patients first and then refers them for adjuvant therapy if 
needed. 
Survival rate: The survival rate refers to the percentage of people in a group who 
are alive for a specific period of time after their diagnosis or treatment (NCCN, 2019b) 
SWOG: The SWOG Cancer Research Network is an NCI supported group that 
conducts clinical trials in adults with cancer. Patients are enrolled in SWOG trials at more 
than 650 institutions in the United States (Unger et al., 2017). 
 Urbanicity: Urbanicity refers to the degree to which a geographical area is urban. 
(Empson et al., 2019) 
Assumptions and Limitations 
There were assumptions made in this study for the accuracy of the SEER 
database. Population-based tumor registries such as those comprising the SEER database 
may have data misclassification and reporting bias. Furthermore, a report demonstrated 
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that population-based registries were particularly variable in the accuracy of radiation 
therapy coding (Walker et al., 2013). This article compared the accuracy of registry 
radiation therapy coding compared with Medicare claims and found that all registries 
studied were not consistent to some degree with Medicare. The registries that were 
examined included those in SEER and the Florida, New York, and Texas state registries. 
The SEER database was more consistent with Medicare than the other state registries. 
The authors summarized the study by commenting that population-based tumor registries 
are critical to oncologic research and that future work should identify the use of 
electronic medical records to improve their accuracy (Walker et al., 2013). But because 
the SEER data are the most widely used for medical research, I assumed that it was 
accurate for my study, which compared relative statistics between races and residence 
locale. Another assumption was made regarding women with Stage I or II breast cancer 
who were ineligible for BCS and radiation therapy by the NCCN criteria. I assumed that 
all women with early-stage breast cancer were recommended to receive radiation therapy 
by their physician because only a small percentage were ineligible due to comorbidities. 
There were limitations to my study related to the possible misclassification of a 
race from medical records. However, this limitation was assumed to be minimal between 
the African American and White races. Another limitation of the SEER database included 
the use of county-based rural/urban residential designations. SEER did not allow for zip 
code classification and therefore I could not perform a more detailed analysis of the 
rural/urban counties. Also, SEER did not record SES status and therefore, no assumptions 
were made on its contribution to the receipt of radiation therapy.  
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Scope and Delimitations 
This doctoral study was limited to female patients with only Stage I and II 
invasive breast cancer. Because male breast cancer was rare, the small number of male 
breast cancers were excluded from my study. However, one national study did determine 
that there existed racial disparities with male breast cancer, and there was increased 
mortality in the African American population (Crew et al., 2007). 
Because the use of a secondary data set was required for my doctoral degree, I 
relied on those variables attainable in the database to answer my research questions. 
Determinants related to patient beliefs and experiences, physician recommendations, 
health literacy rate, and facility quality were not available in this secondary database and 
therefore, not within the scope of this study. No generalizability beyond the state of 
Georgia was implied. 
Significance 
Disparities in breast cancer treatment and survival have persisted for years and 
have increased (McCarthy et al., 2015). African American women and those women 
residing in rural areas experience worse outcomes due to breast cancer than Caucasian 
women and those living in urban areas. African American women have a 40% higher 
breast cancer mortality than White women, even though they have a lower incidence of 
breast cancer (Noone et al., 2016). According to Desantis et al. (2006), African American 
women began having lower rates of breast cancer incidence and higher death rates in the 
1980s. Women with breast cancer who lived outside of urban areas had worse survival 
outcome and tended to underutilize radiation therapy (Lin et al., 2018; Unger et al., 
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2018). Studies have shown that living in the Southeastern United States was associated 
with lower rates of radiation therapy use after lumpectomy than other parts of the country 
(Baldwin et al., 2012; Chagpar et al., 2008; Dragun et al., 2011).  
Therefore, determination of the reasons for the greater mortality rates of 
vulnerable patients is vitally important for the public health of the country. A documented 
reason for worse outcomes in breast cancer care is the lack of adjuvant radiation therapy 
following surgery (Dragun et al., 2011; Martinez, Tseng, et al., 2012; Smith et al., 2010; 
Tuttle et al., 2012; Whelan et al., 2000). Efforts to increase the proper receipt of radiation 
therapy by those who underutilize it, could increase the survivability of breast cancer, the 
most commonly diagnosed cancer in women in the United States (Yeboa et al., 2016). In 
the case of racial minorities, this lower rate of use of an important part of breast cancer 
treatment could be responsible for the fact that the survival rate for African American 
women with breast cancer is lower than that of White women (Hunt & Hurlbert, 2016; 
McCarthy et al., 2015; Ohri et al., 2016; Sighoko et al., 2018). Positive social change is 
promoted by increasing survival from early-stage breast cancer by African American 
women and those residing in rural areas. 
Summary and Conclusions 
The nature of this study focused on quantitative research to understand what 
factors led some women to underutilize radiotherapy even though it was an important 
adjuvant treatment for early-stage breast cancer. Multiple studies have shown that 
adherence to guideline-concordant treatment can be linked to inferior survival in these 
patients (Dragun et al., 2011; EBCTCG et al., 2011; Fang et al., 2018; Hamidi et al., 
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2010; Smith et al., 2010; Tuttle et al., 2012). Radiation therapy eliminates possible 
microscopic disease adjacent to the primary tumor, which is responsible for recurrences 
and the spread to other organs (NCCN, 2019b). The lower rate of use of radiation therapy 
for breast cancer care by African Americans could be responsible for the fact that their 
survival rate is lower than that of White women (Hunt & Hurlbert, 2016; McCarthy et al., 
2015; Ohri et al., 2016; Sighoko et al., 2018).  
Even though multidisciplinary cancer care is available in all large cities in the 
United States, those living in rural areas and racial minorities do not receive radiation 
treatments as often as White women living in urban areas. Continued study of the lack of 
receipt of radiation therapy is warranted to measure the progress or lack of improvement 
in reducing the differences. A review of the literature has not demonstrated a recent study 
of the differences in rates of use of radiation therapy adjusted by race between rural, and 
urban residing women in the South to determine if the disparities have lessened.  
 Interventions have improved access to cancer care, but some populations have not 
seen improved survival rates as a result. Thus, endeavors to continue the monitoring of 
proper breast cancer care receipt are an essential responsibility for public health 
researchers and my goal for this study. Because the lowest rates of use of radiation 
therapy have been shown in be in the Southern region of the United States, this study 
focused on the state of Georgia (Dragun et al., 2011). Analysis of recent updates of the 
SEER registries, and of patients residing in rural areas of the southern United States is not 
available in the literature to my knowledge. Therefore, I aim to increase the knowledge of 
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the receipt of adjuvant radiation therapy for early-stage breast cancer with this doctoral 
study.   
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Section 2: Research Design and Data Collection 
Underutilization of radiation therapy by African American women and women 
residing in rural areas signifies an important disparity in the treatment of early-stage 
breast cancer. Adjuvant radiation therapy following breast-conserving surgery reduces 
the risk of recurrence by two thirds over treatment with surgery alone (EBCTCG et al., 
2011; Fisher et al., 2002). The objective of this doctoral study was to determine the 
association of specific variables with the lack of receipt of radiation therapy in Georgia. 
In this second section of the study, I identify the research design and rationale for 
the study by stating the variables and connecting the research questions to the design. The 
methodology of the study is described by defining the target population, sample size, 
instrument for the secondary data, and the data analysis plan. Finally, I discuss the threats 
to validity and the ethical procedures followed to gain access to the database. 
Research Design and Rationale 
In this doctoral study, I employed the quantitative method for data collection, 
analysis, and interpretation. This method is the best design for an experimental study to 
determine the relationship between the variables (Creswell, 2009). In this study, the 
independent variables were race, county of residence, and health insurance status, and the 
dependent variable was usage of radiation therapy. I used statistical analysis to determine 
the relationship between the independent variables and the patients’ receipt of radiation 
therapy for treatment of early-stage breast cancer. 
I collected national tumor registry data from the SEER database, which is publicly 
available to researchers at no cost. Therefore, there was no time or resource constraints in 
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the collection of data for this study. This represented an advantage to using secondary 
databases as opposed to primary data collected by survey. Collecting high-quality data is 
both expensive and time consuming (Rudestam & Newton, 2015). Another reason why a 
quantitative method was most appropriate for this study was that it was consistent with 
most other prior studies in the literature related to the topic.  
Methodology 
Population 
 The target population for this study was women with early-stage breast cancer 
residing in the state of Georgia. According to the latest statistics from the Georgia 
Department of Public Health (2018), the breast cancer incidence for females in Georgia 
2012–2016 was 36,399. All the records of women with early-stage breast cancer residing 
in Georgia that were available in the SEER 2016 database were included in this study. 
The statistics gathered comprised the most recent and up-to-date set of breast cancer 
records in the state. Because I used this secondary database and records of all female 
patients with early-stage breast cancer were included, random sampling of the data was 
not necessary.  
Sample and Sampling Procedures 
 The exclusion and inclusion criteria focused on collecting the largest population 
groups for statistical significance and for the most health impact. This study only 
included two races because the population of Georgia was comprised of about 60% 
White, 32% African American, and only 8% all other races (U.S. Census Bureau, n.d.).  
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 Only female patients were included because male breast cancer was considered 
rare. In Georgia, only 55 males were diagnosed with breast cancer each year (Georgia 
Department of Public Health, 2018). That was too few to calculate reasonable statistics 
when compared with 36,000 female breast cancer patients. Additionally, the vast majority 
of the literature focusing on breast cancer disparities did not include males.  
 Only early-stage breast cancer was included in this study for a couple of reasons. 
The first reason was that 68% of breast cancers in Georgia were diagnosed as early-stage 
and had the greatest cure rate (Georgia Department of Public Health, 2018). The second 
reason was that the NCCN (2019b) recommended treatment for most early-stage (i.e., 
Stage I and II for this study) was breast-conserving surgery followed by adjuvant 
radiation therapy. Postlumpectomy radiation was contraindicated for women with 
preexisting comorbidities, or women electing mastectomy over breast-conserving 
surgery, and women with poor clinical status (Siegel et al., 2019). However, for the other 
invasive cancer Stages III and IV, radiation therapy was less often widely recommended 
for treatment (NCCN, 2019b). In this study, I focused on breast cancer for which 
adjuvant, postlumpectomy radiation therapy was recommended by NCCN guidelines. 
The anticipated sample size was around 25,000 because 68% of the approximately 
36,000 breast cancer cases in Georgia were early-stage during 2012–2016 (Georgia 
Department of Public Health, 2018). This number was more than sufficient to confidently 
draw conclusions from the results. An adequate sample size is necessary to reach the 
predetermined power or probability sufficient for the test to result in the rejection of the 
null hypothesis (Cohen, 1988). I used an online statistical power calculator to calculate 
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the a priori sample size given the power, alpha, and effect size (see Faul et al., 2007). An 
acceptable power was .80, or the probability that the test detected a true relationship. The 
conventional alpha or significance levels were .05 or .01. By using the larger alpha of .05, 
more opportunities were provided to reject the null hypothesis (see Faul et al., 2007). 
Cohen (1988) suggested a choice of values based on estimations of a small, medium, or 
large effects, which require respectfully decreasing sample sizes. A small effect size of .2 
would require a larger sample but was necessary when the actual variance between the 
test groups was not known. The allocation ratio, or proportion of size of the two study 
groups, was about 2.2 according to the Georgia Department of Public Health (2018). 
Using the G*Power online calculator, the t test for two independent means 
resulted in a sample size of 916 (see Faul et al., 2007). The input values were effect size 
= .2, alpha = .05, power = .8, and allocation ratio = 2.2. The calculated sample size was 
significantly smaller than the study sample. G*Power also allows for the post hoc 
calculation of power if the sample size is known. With this calculation, a sample size of 
520 gave 100% statistical power, which referred to a sure ability to detect a real 
relationship between the variables (see Cohen, 1988). For the logistic regression test, I 
conducted a G*Power calculation that resulted in a sample size of 510, using the same 
input parameters as the t test (see Faul et al., 2007). The post hoc test showed that about 
3,000 samples were needed to reach 100% power. 
I signed the Data Use Agreement for the 1975–2017 SEER Research Data File 
and sent it to SEER. I was then provided with an ID number that allowed me to access 
the database. A separate Data Use Agreement for SEER Radiation Therapy and  
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Chemotherapy Information form was also signed to allow me to gain access to the 
radiation therapy data. 
Instrumentation and Operationalization of Constructs 
In Georgia, the cancer registry process started with requiring all health care 
providers to report specific cancer information on their patient population to the Georgia 
Comprehensive Cancer Registry (GCCR, 2018). The health care providers included 
hospitals, outpatient surgical facilities, laboratories, radiation therapy and chemotherapy 
centers, physicians and their offices, and any other facilities involved in diagnostic 
evaluations or treatment of cancer patients (Georgia Department of Public Health, n.d.). 
The Rollins School of Public Health at Emory University collected and maintained 
cancer data for the GCCR. The Georgia Center for Cancer Statistics (n.d.) at Emory 
University participated in the NCI’s national databases providing population-based 
incidence data as part of the SEER program. The SEER database was the source of the 
secondary data used in this doctoral study. 
 GCCR submitted its data to the North American Association of Central Cancer 
Registries (NAACCR), which is a professional organization that develops data standards 
and certifies cancer registries (Georgia Department of Public Health, 2014). The 
NAACCR evaluates data for completeness, timeliness, and accuracy as well as 
determines whether they meet the National Data Quality Standard. GCCR consistently 
met the National Data Quality Standard criteria and received Gold Certification for the 
past 8 years, which included incidence data from 2008 to 2016, the most recent registry 
data (NAACCR, 2019). This designation allowed the GCCR data to be included in the 
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U.S. Cancer Statistics Registry for Surveillance, the official government statistics on 
cancer, which included the NCI’s SEER program. Gold Certification was the highest 
standard classification that the NAACR used in categorizing registries for inclusion in the 
U.S. National Cancer Statistics. The Gold Standard signified that the cancer registry met 
all the criteria, including 95% completeness in case ascertainment; fewer than 0.1% 
duplicate case reports; all data variables used to create incidence by cancer type, sex, 
race, age, and county were 100% error-free; and others (NAACCR, 2019).  
The SEER Program, therefore, included registry data that satisfied quality 
standards at the state level. In addition, the program included a quality improvement 
process conducted by a staff of statisticians, registrars, and contractors whose goal was to 
monitor and report outcomes and results of data edits, completeness audits, and study 
plans (NCI, n.d.c). The SEER quality improvement staff also set standards for data 
collection by cancer registries and provided technical coding manuals and training 
materials to cancer registrars seeking credentialing. To maintain the high-quality 
standard, the SEER Program developed a broad set of field edits that prevented and 
corrected errors in the data. Electronic edits were also used to authenticate codes as well 
as check for missing data and other errors. I used the most recent SEER database with 
radiation therapy treatment data that was published in April 2019 (SEER, 2019b). 
 The independent variables that were analyzed to answer the research questions 
were race, county of residence in Georgia, and health insurance status. The dependent 
variable was radiation therapy use. These variables were operationalized in the SEER 
Data Record Description for Cases Diagnosed in 1975–2017. The variable for race was 
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coded as 1 for African American and 2 for White. These were the only two codes that 
were used for the study although the race recode had codes for other and unknown. Other 
races likely comprised an exceedingly small and statistically insignificant percentage of 
women undergoing treatment for breast cancer in Georgia. The residence county in SEER 
was operationalized as a state and county Federal Information Processing System Code. 
Georgia’s Federal Information Processing System code was 13 and each county had a 
three-digit code. The insurance status variable consisted of five codes: 1 = uninsured, 2 = 
any Medicaid, 3 = insured, 4 = insured/no specifics, and 5 = insurance status unknown. I 
designated Codes 2, 3, 4 as insured for this study. The dependent radiation therapy 
variable was described by SEER as 1 = external beam, 2 = radioactive implant, 3 = 
radioisotopes, 4 = combination, 5 = radiation not specified, 6 = other radiation, 7 = 
refused radiation therapy, and 8 = none/unknown. Types 1, 2, 3, 4, 5, and 6 were 
designated as “Yes,” received radiation. Types 7 and 8 were designated as “No,” did not 
receive radiation. The other variables used in this study included sex (female), primary 
site (breast), primary surgical site (lumpectomy), and stage (i.e., I, IIA, and/or IIB). 
 Confounding variables could have had a role in obscuring the results of this study. 
In medical research such as this, relationships between cause and effect could be blurred 
by confounders which should be controlled (see Jager et al., 2008). Additionally, 
confounders are variables whose presence affects the variable being studied 
(Pourhoseingholi et al., 2012). One such confounder was patient age, which could 
influence their cancer treatment choice. Older women may not have opted for radiation 
therapy because their mobility was limited making it difficult for them to attend daily 
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radiation therapy treatments. Older women with early-stage breast cancer may have also 
decided with their physician that adjuvant treatment would likely not extend their life. 
Therefore, I stratified the patient age at diagnosis variable to determine the relationship 
between age and receipt of radiation. Another potentially confounding variable was the 
tumor size. Patients with smaller tumors may have opted to not receive further adjuvant 
treatment for their cancer. The AJCC “T” variable designated tumor size. T1a tumors 
were more than 1 but not more than 5 mm in greatest dimension, T1b tumors were more 
than 5 mm but not more than 1 cm, T1c were more than 1 cm but not more than 2 cm, 
and T2 tumors were more than 2m but not more than 5 cm. Therefore, the tumor size 
variable was contained in the breast cancer stage and was controlled by stratifying the 
tumor stage. Typically, in breast cancer research, parameters, such as tumor grade and 
histology, and hormone receptor status may be considered confounding variables and 
should be controlled. However, in this study, I focused solely on the treatment of early-
stage breast cancer with radiation therapy and, therefore, grade, histology, and receptor 
status did not influence whether radiation therapy is recommended. According to the 
NCCN (2019b) Guidelines, all early-stage breast cancer should receive adjuvant radiation 
therapy following breast-conserving surgery regardless of other cancer specific 
parameters.  
Data Analysis Plan 
 The data analysis was conducted with the SEER*Stat (version 8.3.8) statistical 
software program that was provided by the NCI at no cost to researchers when access to 
the databases was approved (SEER, 2020). SEER*Stat was a tool that allowed the 
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researcher to produce statics for studying the impact of cancer on a population. Because 
SEER*Stat only allowed determination of frequencies, distributions, trends, and survival, 
the SEER database was imported in IBM Statistical Package for Social Science (SPSS) 
version 27 for tests of associations and chi-square tests. 
 The first research question was analyzed with a logistic regression test to 
determine the association between patients’ race and use of radiation therapy after 
controlling for patient age at diagnosis. The second question was assessed with a logistic 
regression test to determine if county of residence and health insurance status predicted 
the use of radiation therapy after controlling for patients’ race and age. The following 
table summarized the data analysis plan for this study. All tests utilized the commonly 
used 95% significance. A probability value greater than .05 meant that the results were 
not statistically significant, and the null hypothesis was not rejected. 
Table 1 
Summary of Statistical Tests Used to Test the Hypotheses 
Research Questions Variables Tests 
1. Is there an association between patient race (i.e., African 
American versus White) in the use of radiation therapy for 
treatment of early-stage breast cancer after controlling for 











2. Does patients’ residence (i.e., rural versus urban) and 
health insurance status predict the use of radiation therapy 
for treatment of early-stage breast cancer after controlling 
for race (i.e., African American versus White) and age 
















Threats to Validity 
 Threats to validity exist in most social science research studies and this study was 
no exception. Threats to internal validity may have resulted in untrustworthiness of the 
reported observations and interpretations unless the threats were considered and 
accounted for as much as possible. In this doctoral study,” history” was a type of internal 
threat that was considered. This threat could invalidate results of a study when changes 
occurred over time that affected the study population. In this study the rurality of a 
location of residence for the population could have changed, whereby business 
development increased, and a radiation therapy center was built nearby. If a previously 
rural, low-income area suddenly had access to treatment facilities in proximity, this could 
have affected the results of the study. Another example of this threat was if the study 
population had a change in health insurance coverage, which allowed better access to 
medical treatment. However, the historical internal threat to validity was not valid in this 
study because the time window of the population cancer records was the last 5 years. This 
short time period did not allow large scale changes to development or health insurance, 
which was a political issue. 
 Another potential threat to internal validity involved the under ascertainment of 
radiation therapy rates by SEER (Yeboa et al., 2016). A study of the under ascertainment 
of radiation therapy by SEER registry data suggested that caution was advised when 
using SEER to compare survival rates and receipt of radiation among population groups. 
However, this limitation was rationalized by explaining that in studies of relative rates, 
the under ascertainment of radiation therapy had not been found to vary by race. Also, the 
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authors speculated that reporting of radiation therapy would be consistent year by year, so 
that reporting a trend over time was still valid. 
 Threats to external validity typically involved generalization of the results. I 
would argue that generalization of the findings to the future was not a goal of this study. 
The research questions were designed to use current data to determine if trends in breast 
cancer disparities were decreasing. Therefore, the view of this study was backward in 
time rather than futuristic. Also, actual patient records were to be examined and not 
averages of sample populations. The threats to external validity were thus minimized by 
this study. 
Ethical Procedures 
 The cancer data that make up the SEER database was collected from state-
mandated cancer registries. For example, in Georgia, the Georgia Department of Public 
Health (2018) established the GCCR with funding from the CDC. The GCCR 
participated in the NCI’s national cancer databases, which SEER was associated. The 
ultimate goal of the state and national cancer registries was the reduction of cancer-
related morbidity and mortality through research and education. The registries were 
uniquely capable of achieving the goals by describing cancer through each state and 
providing data for scientific publications. Studies have provided evidence to show how 
cancer registry data can be used to study and improve clinical outcomes and the quality 
of cancer care in the United States. McLaughlin et al., (2010) studied the question of 
whether cancer registries were unconstitutional because the data was collected with 
government funds and without consent or knowledge of patients. As concerns about 
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individual privacy and the alleged indignity of patient’s medical information being 
transmitted to government officials had come into question, the authors sought to answer 
the concerns by analyzing state registry laws. They concluded that state cancer 
registration would survive constitutional review, protects privacy rights in the United 
States, and justifies public health expenditures for government benefits. The authors also 
stated that the benefits of cancer registration outweighed any perceived moral 
considerations regarding human indignity and privacy concerns (McLaughlin et al., 
2010). 
 There were no alternatives to population-based cancer registries that could 
provide accurate and comprehensive epidemiologic assessments of cancer and databases 
such as SEER were necessary for the public health. State registries took great care to 
protect patient and hospital anonymity. No patient identifiers were collected, and 
analyses were reported only at a cumulative level (Bilimoria et al., 2008). Any statistics 
that were gathered contained retrospective data and individual records were not 
discernible. Confidentiality was of paramount importance for all cancer registries and 
there could be no actual or perceived breach of confidentiality in any cancer registry. To 
access the SEER database for this doctoral study, I was required to read, sign, and 
comply with a data-use agreement. The agreement emphasized that protection of patient 
identities was of upmost importance and that every effort had been made to exclude 
identifying information on individual patients. Also, by signing the document, I agreed to 
make no attempt to identify any individuals from the files and would not publish any 
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information on individual patients. Before collection of the data, the Walden IRB 
Approval Number 07-14-20-0618699 was obtained. 
Summary 
 In Section 2, I described the research design and data collection method of my 
doctoral study. The research design was a quantitative method that used a secondary 
database to answer the research questions. The methodology of the study included a 
description of the instrumentation by identifying the Georgia state registry that was 
incorporated into the national cancer registries of the SEER database. Also, possible 
confounding variables were discussed. The independent variables, which were analyzed 
were race, county of residence, and insurance status. The dependent variable was 
radiation therapy use. The data analysis was conducted with the SEER*Stat and SPSS 
statistical software tools. The statistical tests that were run to answer the research 
questions were defined in a table of the data analysis plan. 
 Following the methodology section, I described some threats to internal validity 
of the results of the study. These included the possible change of the health care 
environment over the time span of the study, and the documented fact that use of 
radiation therapy was not always ascertained properly in registry data. However, these 
threats were rationalized by the fact that the time span of the study was relatively short 
and only 5 years. Also, the threat of under validation of radiation therapy codes in the 
database was explained by the fact that it was not likely to be dependent on race.  
 Finally, in this section I described studies which refuted the possible breach of 
confidentiality and constitutionality of state-mandated cancer registries. Considerable 
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efforts were undertaken to ensure these ethical values were not violated. There were 
substantial numbers of research studies on cancer that depended on valid, accurate, and 
confidential data from cancer. The SEER database was well suited for use as a secondary 
database for cancer studies. In Section 3 the statistical analysis of the SEER cases in this 




Section 3: Results and Findings 
The purpose of this study was to determine if African American women in 
Georgia with early-stage breast cancer were receiving adjuvant radiation therapy at a 
greater rate compared with White women in the most recent 5 years than in the past. 
Additionally, a couple of the factors for receipt of radiation therapy were explored by 
race of participants. The research questions were as follows: 
RQ1: Is there an association between patient race (i.e., African American versus 
White) in the use of radiation therapy for treatment of early-stage breast cancer 
after controlling for age at diagnosis among women in Georgia? 
RQ2: Does patients’ residence (i.e., rural versus urban) and health insurance 
status predict the use of radiation therapy for treatment of early-stage breast 
cancer after controlling for race (i.e., African American versus White) and age 
among women in Georgia? 
The hypotheses in the study were that there was an association between race and use of 
radiation therapy and that residence and health insurance status do predict the usage of 
radiotherapy among women in Georgia.  
In Section 3, I review the data collection procedures using a secondary data set 
and the results of statistical tests used to answer the research questions. The first tests are 
run to define the descriptive statistics of the sample. Then, logistic regression tests are 
used to reject or fail to reject the null hypotheses. I use tables and figures to illustrate the 
results. Finally, the answers to the research questions are summarized. 
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Data Collection of Secondary Data Set 
Following receipt of approval from the Walden University IRB in July 2020, I 
signed and executed the SEER Data Use Agreement. This allowed me access to the 
database for research purposes. The agreement stated that I would not attempt to identify 
the patients and that individual case files would only be identified by an ID number. 
Learning the coding system of the vast SEER database proved to be an arduous task and 
selecting the relevant variables for this study was time consuming. However, the 
technical staff at NCI were most helpful and after several months, the selected variables 
were exported in a format readable by SPSS.  Within SPSS, I recoded the variables and 
evaluated the statistical tests. 
 Some changes to the previously detailed data collection process were necessary 
after I examined the database. When the inclusion criteria of only Stage I and II breast 
cancers was applied, the total number of cases was reduced to 22,115. However, this 
amount remained greater than the population sample of 3,000 that was previously 
calculated as required for 100% power. The percentage of African Americans in the 
sample was 28% and Whites made up 72% of the cases. The cases were limited to female 
breast cancer patients diagnosed between the years of 2012 and 2016. This time frame 
includes the last 5 years of cases available in the SEER database and was the focus of this 
study (see SEER, 2019a). Only African American and White patients were included as 
explained previously. I divided breast cancer data into Stages I, IIA, and IIB for early-
stage inclusion rather than use the T designation. The SEER incidence database utilized a 
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stage coding restricted to breast cancer for 1988–2015 data, and a derived stage coding 
for 2016 data (Ruhl et al., 2016). 
Another revision to the original selection criteria was the inclusion of only 
patients from 45 to 79 years of age. Breast cancer patients younger than 45 tend to have 
more aggressive cancer and, thus, are more likely to opt for a course of treatment 
involving a mastectomy. After a mastectomy, radiation therapy may not be recommended 
in cases involving negative nodes, tumors < 5 cm, and margins > 1mm (NCCN, 2019b). 
Patients older than 80 years are less likely to choose radiation treatment due to 
ambulation difficulties and poor health. Additionally, radiation therapy may not be 
necessary for older patients (Tuttle et al., 2012). Therefore, medical and external issues 
confound the guideline concordance of treatment and were avoided by limiting the 
included age groups from 49 to 79 years of age. 
Descriptive Statistics 
 I collected the descriptive statistics of the sample of cases from the three registries 
that included patients from Georgia from 2012 to 2016. The registries were listed as 
Atlanta Metropolitan (1975+), Rural Georgia (1992+), and Greater Georgia (2000+; see 
SEER, 2019b). The Rural Georgia cases were from the counties of Glascock, Greene, 
Hancock, Jasper, Jefferson, Morgan, Putnam, Taliaferro, Warren, and Washington. They 
were indicated in blue on Figure 2. The Atlanta Metropolitan counties included Clayton, 
Cobb, Dekalb, Fulton, and Gwinnett counties and are indicated in green on the map. The 
Greater Georgia registry included all the other 144 counties in Georgia. Therefore, by 
using the Atlanta Metropolitan, Rural Georgia, and Greater Georgia registries, all 
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counties in Georgia were included in the analysis for the first research question. Only 






Map of Georgia Counties  
 
Note. Adapted from Georgia Counties, by The Georgia Department of Transportation, (2012).  
http://www.dot.ga.gov/DriveSmart/MapsData/Documents/Statewide/Counties_Map_122812.pdf 
Table 2 indicated that the total number of cases were 22,115, with the racial 
breakdown of 27.9% African American and 72.1% White. The ages were categorized by 
groupings of 5 years in the database with the greatest number of cases in the 65–69 
group. The year of diagnosis ranged from 2012 to 2016, with a majority of patients 
diagnosed in 2016. Stages I and II were included for early-stage breast cancer, and the 
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SEER database further divided Stage II into IIA and IIB. The greatest number of cases 
were Stage I (59.6%). The three Georgia registries included were Atlanta (33.9%), Rural 
Georgia (1.7%), and Greater Georgia (64.5%). 
Table 2 
 
Georgia Patient Characteristics Year of Diagnosis 2012-2016 
 Number Percentage 
Total 22,115 100.0% 
Race 
   African American 
   White 
 







   45–49 
   50–54 
   55–59 
   60–64 
   65–69 
   70–74 
   75–79 
 
Stage 
   I 
   IIA 
   IIB 
 
Residence 
   Metro Atlanta  
   Greater Georgia 
   Rural Georgia 
 
Year of diagnosis 
   2012 
   2013 
   2014 
   2015 





















































The database included a variable indicating the type of radiation therapy received. 
For all types, including beam radiation, brachytherapy, radioisotopes, combination of 
beam with implants, and radiation not specified, I recoded the variable “Yes.” If the type 
was listed as none or refused, it was recoded as “No.”  The number of women in Georgia 
aged 45–79 diagnosed between 2012 and 2016 with early-stage breast cancer who 
received radiation therapy was 12,235 (55.3%). The number of women who did not 
received radiation therapy was 9,880 (44.7%). 
Bivariate Analyses 
 I examined the age and stage variables were examined to determine if there was a 
significant association between the races. Table 3 lists the numbers of White and African 
Americans who received radiation therapy for each stage of cancer. As seen, the majority 
of both African American and White women who received radiation therapy had Stage I 





Use of Radiation Therapy by Race and Stage in Georgia 
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Note. Data are from SEER (2019a).  
Pearson chi-square = 232.500, df = 2, p = .000. 
I performed the same chi-square analysis on the different age groups for Whites 
and African Americans to determine the association of use of radiation. Figure 3 shows 
the age groups for radiation use. Most White women who received radiation were in the 
65–69 age group (19.5%), and most African American women who received radiation 
therapy were in the 60–64 age group (18.2%). The association between age and radiation 




Age at Diagnosis of Women With Early-Stage Breast Cancer Who Received Radiation 
Therapy in Georgia 2012–2016 
 
Note. Data are from SEER (2019a).  













Research Questions and Hypotheses 
The research questions and hypotheses were restated below. Following each 
question, the relevant statistical tests and results were given. Table 4 indicates the 
recoding that was necessary to run binary logistic regression tests. 
Table 4 
 
Recoding of Dependent and Independent Variables 
 Recode  
Radiation use   
   Yes 





   African American 
   White 
 





   45-49 
   50-54 
   55-59 
   60-64 
   65-69 
   70-74 
   75-79 
 
Residence 
   Metro Atlanta  
   Rural Georgia 
 
Insurance status 
   Yes 
   No 























Research Question 1 Results  
The first question was answered using a logistic regression test. The results were 
not significant, and the null hypothesis was not rejected.  
RQ1: Is there an association between patient race (i.e., African American versus White) 
in the use of radiation therapy for treatment of early-stage breast cancer after controlling 
for age at diagnosis among women in Georgia? 
H01: There is no significant association between race in the use of radiation 
therapy for treatment of early-stage breast cancer after controlling for age at 
diagnosis among women in Georgia. 
Ha1: There is a significant association between race in the use of radiation therapy 
for treatment of early-stage breast cancer after controlling for age at diagnosis 
among women in Georgia. 
A binary logistic regression analysis was conducted to investigate if patient race 
was associated with use of radiation therapy for treatment of early-stage breast cancer 
after controlling for patients’ age. The outcome variable was radiation therapy usage and 
possible predictor variables were race and age. Initially the regression test was run with 
race as the predictor variable. This analysis revealed that race was not a predictor of 
radiation therapy use because the independent variable was not significant (p = .201). 
Patient age was next added as a controlling variable and the model showed that race was 
still not a predictor (p = .517). However patient age was significant and therefore a 
predictor of radiation therapy use (p = .000). The unstandardized B value was negative (B 
= -.045) and Exp(B) = .956. The reference value for the radiation therapy variable was 
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“Yes.” Therefore, for every 5-year increase in age, the odds ratio for radiation therapy 




Age and Race Association With Radiation Therapy Use for Women in Georgia 
Diagnosed 2012-2016 




Race .020 .030 .420 1 .517 1.020 .961 1.082 
Age -.045 .008 35.999 1 .000 .956 .942 .970 
Constant .390 .035 123.878 1 .000 1.477   
Note. Data are from SEER (2019a). Variable reference: Radiation therapy = Yes 
 There was not statistically significant association in the use of radiation therapy 
for the treatment of early-stage breast cancer between White and African American 
women in Georgia during the years of 2012 and 2016. Therefore, the null hypothesis 
failed to be rejected after controlling for age. 
 
Research Question 2 Results  
The second question was answered with a logistic regression test, which used the 
independent variables of patient residence and health insurance status. The dependent 
variable was radiation therapy usage. The regression test did not show an association 
between residence and health insurance status with radiation therapy usage, and 
therefore, the null hypothesis was not rejected. 
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RQ2: Does patients’ residence (i.e., rural versus urban) and health insurance 
status predict the use of radiation therapy for treatment of early-stage breast cancer after 
controlling for race (i.e., African American versus White) and age among women in 
Georgia? 
H01: Patients’ residence, and health insurance status do not predict the use of 
radiation therapy for treatment of early-stage breast cancer after controlling for 
race (i.e., African American versus White) and age among women in Georgia. 
Ha1: Patients’ residence, and health insurance status do significantly predict the 
use of radiation therapy for treatment of early-stage breast cancer after controlling 
for race (i.e., African American versus White) and age among women in Georgia. 
For RQ2 the SEER registry variable indicating residence was imported along with 
the radiation variable for each case selected using the criteria of female African American 
or White with breast cancer, aged 45–79, diagnosed during the years of 2012 and 2016, 
and residing in Georgia. Of the three registries, Atlanta Metro, Rural Georgia, and 
Greater Georgia, only the Atlanta and Rural registries were included to determine the 
association between radiation use among African American and White women residing in 
rural and urban counties. The health insurance status variable along with the radiation 
treatment variable was imported to SPSS for each case. Insurance variable was recoded to 
“Yes” for insured and Medicaid types, and “No” for those insured. The 401 cases, which 
indicated insurance unknown, were not included in this analysis. Table 5 lists the 





Patient Characteristics of Women Residing Only in Urban and Rural Counties 
Diagnosed 2012–2016 
 Number Percentage 
Total 7,861 100% 
Race 
   African American 








   Metro Atlanta  
   Rural Georgia  
 
Insurance status 
   No 
   Yes 
 
Radiation therapy after 
surgery 
   No 

























Note. Data are from SEER (2019a). 
 
A binary logistic regression analysis was run to determine whether the 
independent variables of patients’ residence and health insurance status predicted the 
outcome variable of radiation therapy use while controlling for patients’ race and age. In 
Block 1 of the analysis, residence (p = .610) and insurance status (p = .153) did not 
significantly predict radiation therapy use. In Block 2 of the model patients’ race and age 
were included as control variables. The result indicated that the independent variables of 
residence (p = .644) and insurance status (p = .143) still did not predict radiation therapy 
usage. The B values for residence (B = -.049) and health insurance status (B = -.243) were 
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both negative indicating that urban residence (i.e., Atlanta Metro) and affirmative health 
insurance status were associated with radiation therapy use. The logistic regression 
analysis is reported in Table 7. 
Table 7 
Residence, Insurance Status, Age, and Race Association With Radiation Therapy Use for 
Women in Georgia Diagnosed 2012-2016 






















Insurance -.243 .166 2.143 1 .143 .785 .567 1.086 
Age .000 .013 .000 1 .986 1.000 .975 1.025 
Constant .205 .059 12.110 1 .001 1.227   
Note. Data are from SEER (2019a). Variable references: Radiation therapy = Yes, Residence = Atlanta, 
Insurance status = Yes 
The null hypothesis failed to be rejected because patients’ residence and health 
insurance status did not significantly predict radiation therapy use after controlling for 
race and age.   
Summary 
 The statistical analysis of the SEER data revealed interesting and encouraging 
results. Even though the hypotheses of the study were not consistent with the data, the 
results showed that African American women in Georgia were receiving radiation 
therapy more often compared to White women that in the past. The most recent years that 
the SEER registries were available included 2012–2016.  
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The first research question asked if there was a significant association between 
African American and White women’s race and their use of radiation therapy in Georgia 
after controlling for their age? The data revealed that there was not a significant 
association in the use of radiation between women of the two races. The null hypothesis, 
which stated that there was no significant association, failed to be rejected.  
 The second research question focused on residence in rural versus urban counties 
in Georgia and health insurance status. The question was whether the independent 
variables predicted the use of radiation therapy. The logistic regression model showed 
that they did not significant predict the dependent variable and therefore, the null 
hypothesis was not rejected.  
  In Section 4, interpretations of the results, the application of the study to 
professional practice and implication for social change will be discussed. The findings of 
the statistical analysis of the secondary data will be compared with that found in the 
literature described in Section 1. The findings are then analyzed in the context of the 
theoretical framework of ABM. The limitations of the study along with recommendations 
for further research in breast cancer treatment disparities are described. My 
recommendations for the application of the study for professional practice and the 




Section 4: Application to Professional Practice and Implications for Social Change 
I conducted this retrospective quantitative study to extend the knowledge gained 
from prior research into the underutilization by African American women of radiation 
therapy for early-stage breast cancer in Georgia. The study was designed to determine the 
rate of receipt of radiation therapy and the association with two factors that could be 
reasons for the utilization disparities. I analyzed secondary data from the SEER database 
of the NCI. 
Implications for Findings 
The two research questions were answered by the findings. I developed the first 
question to determine whether there was a significant association in the rate of use of 
radiotherapy for the treatment of early-stage breast cancer and race among women in 
Georgia after controlling for their age. The corresponding null hypothesis failed to be 
rejected. There were no statistically significant association between use of radiotherapy 
for treatment of early-stage breast cancer and race. 
The literature, as cited in Section 1, contained a consensus that African American 
women underutilize radiation therapy compared to White women in previously published 
studies. Bickell et al. (2007) showed African American women had twice the risk of 
White women for not receiving adjuvant radiation therapy for early-stage breast cancer. 
Sail et al., (2012) demonstrated similar results and further determined that the disparities 
in receipt of radiation therapy were increasing. Tuttle et al. (2012) conducting the largest 
study to date of more than 294,000 women, showed a significantly greater percentage of 
White women received radiation therapy than African American women for 
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postlumpectomy breast cancer. Their study included data for women diagnosed with 
breast cancer from 1992 through 2007 from the SEER database. 
Further prior studies revealed evidence that reflect disparities. Markossian and 
Hines (2012) examined the disparities in late-stage breast cancer experienced by women 
in Georgia by also using SEER data from 1992–2007 to calculate odds ratios for receipt 
of surgery and radiation therapy. Their results showed that urban residents were more 
likely to receive surgery and radiation therapy compared with rural residents. Martinez, 
Shah et al. (2012) further showed that the problem of rural radiation treatment access 
affected African American women more so than White women. The study using the most 
recent patient data was conducted by Yeboa et al. (2016). In their study, the SEER 
database was used to analyze patient cases diagnosed between 2004 and 2009, and the 
researchers determined that not only did the use of lumpectomy with radiation therapy 
decrease over the study period but that the decrease in radiation therapy use with African 
American women was double that of White women. Parekh et al., (2018) studied the 
impact of race and other factors on receipt of radiation after breast-conserving surgery, 
concluding that of the women under the age of 70 who underwent surgery for breast 
cancer from 2004 to 2014, White women were significantly more likely to receive 
radiation therapy than African American women (90.2% versus 85.3%, p < .0001). Their 
study did, however, provide a somewhat agreeable finding to the current study because 
the authors showed that the percentage of women nationwide receiving radiation therapy 
after breast surgery decreased in 2013 and 2014, the last years of their study. 
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Therefore, there was much evidence of the underutilization of radiation therapy 
by African American women compared to White women published in the scientific 
literature. The goal of this study was to analyze data from the most recent SEER database 
of women diagnosed with early-stage breast cancer diagnosed between 2012 and 2016 in 
Georgia to determine if the trend of racial disparities had continued or improved. 
With the second research question, I sought to examine whether patients’ county 
of residence in Georgia and their health insurance status predicted their use of 
radiotherapy for early-stage breast cancer. The analysis showed that residence and health 
insurance status did not significantly predict radiation therapy use, and thus, the null 
hypothesis failed to be rejected. Unlike the previously reported studies in the literature, 
the percentage of women living in rural counties of Georgia received radiation therapy in 
a greater percentage than those who did not; however, the rural versus urban residence 
usage of radiation therapy was not found to be statistically significant.  
Contrary to the results of the current study, the scientific literature reported that 
rural versus urban residential disparities exist in breast cancer treatment and mortality. 
Rural women in Georgia were found to have a higher death rate due to breast cancer than 
those living in urban areas (Markossian et al., 2014). In another study of rural patients in 
Georgia, Guy et al. (2015) found that only 35.2% received guideline-concordant 
treatment including radiation therapy for early-stage breast cancer. Furthermore, the 
problem of rural treatment access affected African American women more so than 
Whites (McClelland et al., 2017; Unger et al., 2018). 
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Accessibility to radiation therapy had been studied in the literature and shown to 
be a factor in radiation therapy usage in rural areas and urban residential counties. Recent 
literature supported the idea that increased travel distance to radiation therapy facilities in 
rural areas reduced the likelihood of receipt of radiation therapy (Lin et al., 2018; 
Longacre et al., 2019; Unger et al., 2018). Data from the Radiological Physics Center at 
MD Anderson in Houston, Texas and my personal knowledge of Georgia radiation 
therapy centers revealed that there were no treatment facilities in any of the 10 counties 
in the SEER rural Georgia registry (Radiological Physics Center, n.d.). Therefore, those 
women residing in the rural counties had to use private or public transportation to get to 
their radiation treatments. There were relatively few (371) women with Stages I or II 
breast cancer residing in these counties and diagnosed during the study period. 
 Studies in the literature have also demonstrated that lack of health insurance 
coverage in women with breast cancer was related to omission of radiation therapy after 
lumpectomy (Churilla et al., 2017; Freedman et al., 2011; Parekh et al., 2018). In a study 
of SEER data of early-stage breast cancer patients, Churilla et al. (2017) found a 10% 
difference in rates of omission of radiation therapy following surgery according to health 
insurance status. In an older study, a 12% difference was reported in radiation therapy 
usage rates between insured and uninsured patients in the National Cancer Database 
(Freedman et al., 2011). 
 I used ABM as the conceptual framework of this study. The ABM enabling 
factors of health insurance and accessibility (i.e., residence) were most relevant and were 
used to determine if the radiation therapy health service was associated to them. Further 
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investigation is needed to analyze the affects that the health service has on the survival 
outcome.  
Limitations of the Study 
This study had inherent limitations related to the use of population-based tumor 
registries. The SEER database used was comprised of registries throughout Georgia that 
were subject to data misclassification. Specifically, reporting biases had been 
demonstrated in the inaccuracy of radiation therapy coding for Medicare claims (Walker 
et al., 2013). Discrepancies in registry recorded treatment and the actual treatment 
delivered to the patient may also exist. The weakness of tumor registry-based databases 
was, however, balanced by the ability of researchers to analyze large sample sizes. 
Therefore, the scientific literature heavily relied on SEER databases for most 
retrospective studies, and the database was used in the majority of the studies found in 
my literature search. SEER specifically listed the high overall sensitivity of the radiation 
therapy usage data as > 85%, which was determined by Noone at al. (2016). This 
limitation related to database use was due to the incompleteness of the radiation therapy 
variables as defined by tumor registries (see Jagsi et al. 2012). Additionally, the lack of 
data on systemic therapy in the SEER data could affect treatment decisions (Churilla et 
al., 2017). 
 An additional weakness in the SEER database was the lack of case-specific SES. 
The rural and urban residential counties in the SEER registries were defined by Georgia 
Center for Cancer Statistics (n.d.). Because only the county was known to me in the 
database, I could not draw any conclusions of income or education level. These factors 
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could vary substantially in a county and may have an impact on treatment. I used the 
rural Georgia registry in SEER; however, there could be other rural counties in Georgia 
that may have led to different findings in this study. 
 Finally, there are patient and medical factors that affect cancer treatment decisions 
that were not captured in this study. Variables, such as progression of disease, response to 
chemotherapy and surgery, comorbidities, and hormone receptor positivity, could all 
influence a physician or patient’s treatment choice. In addition, provider biases toward 
certain treatments, family history, and patient fears about radiation therapy could have 
impacted their decision. A limitation as cited by SEER was the biases associated with 
unmeasured reasons for receiving or not receiving radiation therapy and/or chemotherapy 
(see Noone et al., 2016). 
 Care should be taken with regard to comparison of the results of this study to 
other areas in the United States. No generalizability beyond Georgia was intended 
because the analyses were limited to the SEER registries of Atlanta, rural Georgia, and 
greater Georgia. However, the population may be representative enough of the 
southeastern U.S. population in demographics and economics to warrant that comparison. 
Recommendations 
 Future study of the disparities in early-breast cancer treatment was needed and, 
therefore, was the inspiration of this study. While the results did not follow the trends 
seen in the literature, they have justified a much larger nationwide study to validate that 
the disparities in breast cancer treatment were on the decline. The interventions that have 
been put in place by organizations such as the Avon Foundation in Atlanta can be having 
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a significant impact in erasing racial and economic disparities in breast cancer. The true 
test of the interventions, however, will be whether survival rates were affected. 
 Another aspect of breast cancer treatment that can have had an impact in the 
findings is the widespread adoption of innovation in radiation therapy. In the past, the 
common dose and fractionation of radiation therapy after surgery called for 5 to 7 weeks 
of daily treatment. More recently, clinical trials have demonstrated that the use of shorter 
courses of therapy have comparable outcomes and toxicity with long-term treatment 
(Smile et al., 2016). These types of novel radiation schemes, called accelerated partial-
breast irradiation and hypofractionated whole breast irradiation, have been receiving 
wide-spread implementation. Hypofractionated whole breast irradiation radiation 
treatments are delivered in as few as 15 fractions, which greatly reduce the number of 
times patients must visit the facility and also the cost of treatment. A particularly 
innovative type of treatment, called intraoperative radiotherapy, is delivered in one 
session in the operating room, immediately after a lumpectomy. It has been popular with 
patients in the limited number of facilities where it is offered. The increased convenience 
of shorter courses of treatment may improve compliance by patients to complete their 
therapy. 
Implications for Professional Practice and Social Change 
 This study has delivered an important addition to the evidence of eliminating 
disparities in breast cancer care. Previously, the trends of underutilization of radiation 
therapy were thought to be a cause of declining survivability by African American 
women in the southern United States. However, as shown by the results of this study, 
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recently the rate of use of radiation therapy by African Americans and those living in 
rural areas has been increasing. Although the results were not significant, a trend may be 
starting to occur. 
 While this good news shows a movement toward less disparities, in the 
professional practice of radiation therapy, much is still needed to ensure the equitable 
delivery of breast cancer care. For instance, fulfilling transportation needs for patients to 
attend appointments for physician visits, treatment, and follow up would help to ensure 
that all patients are given access. The use of health care navigators can also help patients 
find their way through the complicated maze of multidisciplinary breast cancer care. This 
may reduce the likelihood of some patients being lost in the network of breast care 
specialists. 
Another important strategy that can further influence receipt of radiation therapy 
is the development of a more culturally competent medical workforce. Diversification of 
the physician workforce may help to improve outcomes for African Americans because 
they are underrepresented in most oncological specialties (McClelland et al., 2017). A 
workforce study done by the American Society for Radiation Oncology in 2017 
determined that only 2% of U.S radiation oncologists were African American (Fung et 
al., 2019). Current interventions to enhance the cultural competence training of medical 
providers and staff can lead to less bias and more understanding of the ability to care for 
diverse populations. 
           This study impacts social change by providing evidence for the positive changes to 
breast cancer treatment with radiation therapy. Disparities in breast cancer treatment and 
68 
 
survival have persisted for decades leading up to this study. Previously shown in the 
literature, African American women and those residing in rural areas experienced a 
higher mortality rate due to breast cancer than Whites and those living in urban areas 
(McCarthy et al., 2015; McLafferty et al., 2011; Sighoko et al., 2018). This public health 
issue has received much attention in recent years and interventions to turn around the 
trend have been instituted. The Radiation Oncology Institute (n.d.), a nonprofit 
foundation, works to increase the knowledge of the critical role of radiation therapy in the 
treatment of cancer through the funding of research and education. Along with other 
advocacy groups, the Radiation Oncology Institute is working to improve diversity and 
inclusion in radiation therapy that will improve cancer care and outcomes. This study 
demonstrates that these efforts may be beneficial for many patients. 
Conclusion 
The goal of this study was to supplement the literature with recent data regarding 
disparities in radiation therapy for early-stage breast cancer treatment. I used the most 
current SEER registries from Georgia to determine whether the trends in underutilization 
of radiation therapy by African American women and those residing in rural areas have 
continued. The results from early-stage breast cancer patients diagnosed from 2012–2016 
indicated that the trend has started to reverse and that the use of radiation therapy by 
those populations has increased to that of the rates of White women and those living in 
urban Atlanta. For far too long, disparities in survival rates for breast care have widened 
to the point of a public health crisis. The barriers to improving the survival rates may be 
breaking down, and as seen in the results of this study, breast cancer treatment is 
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becoming more equitable across racial and geographic boundaries in Georgia. The 
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